{
    "id": 20806,
    "fullName": "BRD4 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "BRD4 positive indicates the presence of the BRD4 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 23476,
        "geneSymbol": "BRD4",
        "terms": [
            "BRD4",
            "CAP",
            "HUNK1",
            "HUNKI",
            "MCAP"
        ]
    },
    "variant": "positive",
    "createDate": "04/07/2016",
    "updateDate": "05/27/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20473,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ARV-771 treatment reduced Brd4 expression, and induced apoptosis in ABC-like diffuse large-B-cell lymphoma cell lines harboring copy gains in TCF4 and expressing BRD4 in culture, and inhibited tumor growth in cell line xenograft models (PMID: 31217338).",
            "molecularProfile": {
                "id": 21298,
                "profileName": "BRD4 positive"
            },
            "therapy": {
                "id": 9364,
                "therapyName": "ARV-771",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17851,
                    "pubMedId": 31217338,
                    "title": "Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31217338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8098,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CPI-203 treatment of pancreatic ductal adenocarcinoma (PDAC) cells expressing BRD4 resulted in decreased cell viability in culture and inhibition of tumor growth in PDAC cell line xenograft models (PMID: 27169995).",
            "molecularProfile": {
                "id": 21298,
                "profileName": "BRD4 positive"
            },
            "therapy": {
                "id": 4633,
                "therapyName": "CPI-203",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6549,
                    "pubMedId": 27169995,
                    "title": "Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27169995"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14058,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX51107 inhibited CpG-induced proliferation and overcame stromal-mediated protection from apoptosis in BRD4-expressing primary chronic lymphocytic leukemia (CLL) cells in culture, and reduced tumor burden and modulated BRD4-target expression in BRD4-expressing CLL mouse models, and prolonged survival, decreased tumor burden, and reduced spleen size and lymph node mass size in models of Richter transformation (PMID: 29386193).",
            "molecularProfile": {
                "id": 21298,
                "profileName": "BRD4 positive"
            },
            "therapy": {
                "id": 6999,
                "therapyName": "PLX51107",
                "synonyms": null
            },
            "indication": {
                "id": 1040,
                "name": "chronic lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11435,
                    "pubMedId": 29386193,
                    "title": "BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29386193"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5607,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, dBET1 treatment decreased Brd4 protein level and induced apoptosis in acute myeloid leukemia cells in culture, and delayed tumor progression in xenofgraft models (PMID: 25999370).",
            "molecularProfile": {
                "id": 21298,
                "profileName": "BRD4 positive"
            },
            "therapy": {
                "id": 3907,
                "therapyName": "dBET1",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5123,
                    "pubMedId": 25999370,
                    "title": "DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25999370"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10854,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BETd-246 induced degradation of Brd2, Brd3, and Brd4, resulted in apoptosis of triple-receptor negative breast cancer cell lines in culture, and inhibited tumor growth in cell line xenograft models (PMID: 28209615).",
            "molecularProfile": {
                "id": 27776,
                "profileName": "BRD2 pos BRD3 pos BRD4 pos"
            },
            "therapy": {
                "id": 5603,
                "therapyName": "BETd-246",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8792,
                    "pubMedId": 28209615,
                    "title": "Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28209615"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 21298,
            "profileName": "BRD4 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27776,
            "profileName": "BRD2 pos BRD3 pos BRD4 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}